2Q FY26 Quarterly Activity Report and Appendix 4C
| Stock | Adheris Health Limited (AHE.ASX) |
|---|---|
| Release Time | 30 Jan 2026, 9:38 a.m. |
| Price Sensitive | Yes |
Adheris Health Q2 FY26 Report and Appendix 4C
- New CEO John Ciccio appointed, with focus on stabilising business, rebasing costs, and converting pipeline
- Q2 FY26 revenue down 45.8% to $13.7m, gross profit down 57.5% to $6.5m
- Successful launch of new technology platform, with additional features to be rolled out in Q3 FY26
- Focus on delivering commercial and operational benefits, accelerating digital innovation and improving delivery
Adheris Health Limited (ASX: AHE) has released its quarterly activities report and Appendix 4C for the three months ended 31 December 2025 (Q2 FY26). Key highlights include the appointment of John Ciccio as CEO and Managing Director, with a focus on stabilising the business, rebasing operating costs, and converting pipeline opportunities. The company has also made achievements such as enhancements to the executive management team, delivery of a material cost-out program, and re-engagement with former customers. Q2 FY26 operating revenue was $13.7 million, down 45.8% on the prior corresponding period (Q2 FY25: $25.3 million), due to lower customer renewal rates, lower vaccine revenue, and lower average deal sizes. Gross profit and gross margin also decreased, reflecting the lower revenue, allocation of platform costs, and a shift in product mix. The company has launched a new technology platform, which enables accelerated digital innovation and more efficient program execution, with additional features and functionality to be rolled out in Q3 FY26. The focus now shifts to delivering commercial and operational benefits, accelerating digital product innovation, improving delivery and execution, and embedding AI to drive enhanced personalization and deeper patient engagement.
The company expects staff costs to drop to approximately $3.6 million in Q4 FY26 as the impact of recent changes flows through the business.
The company is focused on building a more resilient revenue base by reducing its reliance on vaccine programs and expanding into high-growth therapeutic categories and complex specialty conditions. It is also prioritising higher-margin solutions such as THRiV and digital messaging, expanding its pharmacy network, and enhancing its digital engagement capabilities.